Blocking Fructose Metabolism Shows Promise Against Pediatric Brain Cancer
New research from Johns Hopkins reveals that disrupting fructose metabolism in tumor cells could slow group 3 medulloblastoma, a deadly childhood brain cancer, offering a potential new treatment avenue.
Researchers at Johns Hopkins Medicine have identified a potential new approach to treating group 3 medulloblastoma, an aggressive and hard-to-treat pediatric brain cancer. In mouse experiments, blocking the metabolism of fructose in tumor cells slowed the progression of the disease, according to a study published in Acta Neuropathologica Communications and conducted at the Kimmel Cancer Center.
The findings suggest that disrupting how tumor cells generate energy could be a viable strategy against this deadly cancer, which currently has limited treatment options and a poor prognosis. The research team demonstrated that medulloblastoma cells rely heavily on fructose metabolism for energy, and inhibiting this process reduced tumor growth in mouse models.
This discovery could pave the way for new therapies that target the metabolic vulnerabilities of cancer cells. The study's lead author noted that understanding the specific metabolic pathways used by tumor cells is crucial for developing more effective treatments with fewer side effects.
The announcement comes amid growing interest in metabolic approaches to cancer treatment. For-profit firms like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are also focused on developing next-generation treatments for glioblastoma and other brain cancers, highlighting the urgent need for innovative therapies in this field.
Medulloblastoma is the most common malignant brain tumor in children, and group 3 is the subtype with the worst survival rate. Current treatments, including surgery, radiation, and chemotherapy, often lead to long-term cognitive and developmental side effects. A targeted therapy that disrupts fructose metabolism could potentially offer a less toxic alternative.
The research team plans to further investigate the mechanisms by which fructose metabolism supports tumor growth and explore ways to translate these findings into clinical trials. If successful, this approach could represent a significant advance in the treatment of pediatric brain cancer.
This study adds to a growing body of evidence that targeting cancer metabolism is a promising avenue for drug development. By cutting off the energy supply to tumor cells, researchers hope to halt their growth while sparing healthy cells.